Indivior Pharmaceuticals (FRA:E7P) FFO


FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
56 GF Score
Price €36.00
GF Value €19.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:E7P
56GF Score
Indivior Pharmaceuticals Inc FRA:E7P
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €36.00 is trading 83.9% above its estimated GF Value™ of €19.58. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • FFO:
  • GF Value™: €19.58 vs. price of €36.00 (83.9% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
56GF Score

Get the complete analysis for FRA:E7P

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€36.00
Price
€19.58
GF Value